New Insights into Diagnostic and Prognostic Biomarkers of Amyotrophic Lateral Sclerosis: Must Innovative Findings Come from New Targets?

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: closed (15 June 2024) | Viewed by 1491

Special Issue Editor


E-Mail Website
Guest Editor
1. Biochemistry Department, Tours University Hospital, 37000 Tours, France
2. INSERM 1253, iBrain, University of Tours, Inserm, 37000 Tours, France
Interests: metabolomic analysis; amyotrophic lateral sclerosis; biomarkers

Special Issue Information

Dear Colleagues,

Amyotrophic lateral sclerosis (ALS) remains a hot topic in the field of neurological research as no diagnosis, prognosis, and efficient treatment are available today. Although progress in exploratory methods is revolutionizing the research, especially on biomarkers, and the diversity of experimental models offers new opportunities to depict ALS, the topic of whether knowledge improvement must mandatorily come from rupture innovation is still up for debate. More specifically, we can suspect that the deep exploration of some targets has been abandoned to move toward more attractive and spectacular ones. Similarly, basic exploration methods for biomarkers have been replaced by omics, and standard data analysis has been replaced by artificial intelligence. However, research on more powerful and ambitious approaches may hide relevant findings based on more standard methods.

This Special Issue of Biomolecules will focus on the most recent advances in relation to 1) well-known targets described for many years but explored in different ways (SOD1, TDP-43, etc.), 2) isolated biomarkers provided by both targeted methods and large omics strategies, 3) promising results from standard experimental models, even if old and questionable, and 4) the mode effect via the exploration of ways largely described in several neurological diseases but rarely in ALS.

Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome.

Dr. Hélène Blasco
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • omics
  • animal models
  • innovation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 3067 KiB  
Article
Shotgun Proteomics Links Proteoglycan-4+ Extracellular Vesicles to Cognitive Protection in Amyotrophic Lateral Sclerosis
by Beatrice Vilardo, Fabiola De Marchi, Davide Raineri, Marcello Manfredi, Veronica De Giorgis, Alen Bebeti, Lorenza Scotti, Natasa Kustrimovic, Giuseppe Cappellano, Letizia Mazzini and Annalisa Chiocchetti
Biomolecules 2024, 14(6), 727; https://doi.org/10.3390/biom14060727 - 19 Jun 2024
Viewed by 1021
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder lacking reliable biomarkers for early diagnosis and disease progression monitoring. This study aimed to identify the novel biomarkers in plasmatic extracellular vesicles (EVs) isolated from ALS patients and healthy controls (HCs). A total of [...] Read more.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder lacking reliable biomarkers for early diagnosis and disease progression monitoring. This study aimed to identify the novel biomarkers in plasmatic extracellular vesicles (EVs) isolated from ALS patients and healthy controls (HCs). A total of 61 ALS patients and 30 age-matched HCs were enrolled in the study and the protein content of circulating EVs was analyzed by shotgun proteomics. The study was divided into a discovery phase (involving 12 ALS and 12 HC patients) and a validation one (involving 49 ALS and 20 HC patients). In the discovery phase, more than 300 proteins were identified, with 32 proteins showing differential regulation in ALS patients compared to HCs. In the validation phase, over 400 proteins were identified, with 20 demonstrating differential regulation in ALS patients compared to HCs. Notably, seven proteins were found to be common to both phases, all of which were significantly upregulated in EVs from ALS patients. Most of them have previously been linked to ALS since they have been detected in the serum or cerebrospinal fluid of ALS patients. Among them, proteoglycan (PRG)-4, also known as lubricin, was of particular interest since it was significantly increased in ALS patients with normal cognitive and motor functions. This study highlights the significance of EVs as a promising avenue for biomarker discovery in ALS. Moreover, it sheds light on the unexpected role of PRG-4 in relation to cognitive status in ALS patients. Full article
Show Figures

Figure 1

Back to TopTop